Cargando…
Proteomics-Driven Biomarkers in Pancreatic Cancer
Pancreatic cancer is a devastating disease that has a grim prognosis, highlighting the need for improved screening, diagnosis, and treatment strategies. Currently, the sole biomarker for pancreatic ductal adenocarcinoma (PDAC) authorized by the U.S. Food and Drug Administration is CA 19-9, which pro...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443269/ https://www.ncbi.nlm.nih.gov/pubmed/37606420 http://dx.doi.org/10.3390/proteomes11030024 |
_version_ | 1785093788535881728 |
---|---|
author | Ramalhete, Luís Vigia, Emanuel Araújo, Rúben Marques, Hugo Pinto |
author_facet | Ramalhete, Luís Vigia, Emanuel Araújo, Rúben Marques, Hugo Pinto |
author_sort | Ramalhete, Luís |
collection | PubMed |
description | Pancreatic cancer is a devastating disease that has a grim prognosis, highlighting the need for improved screening, diagnosis, and treatment strategies. Currently, the sole biomarker for pancreatic ductal adenocarcinoma (PDAC) authorized by the U.S. Food and Drug Administration is CA 19-9, which proves to be the most beneficial in tracking treatment response rather than in early detection. In recent years, proteomics has emerged as a powerful tool for advancing our understanding of pancreatic cancer biology and identifying potential biomarkers and therapeutic targets. This review aims to offer a comprehensive survey of proteomics’ current status in pancreatic cancer research, specifically accentuating its applications and its potential to drastically enhance screening, diagnosis, and treatment response. With respect to screening and diagnostic precision, proteomics carries the capacity to augment the sensitivity and specificity of extant screening and diagnostic methodologies. Nonetheless, more research is imperative for validating potential biomarkers and establishing standard procedures for sample preparation and data analysis. Furthermore, proteomics presents opportunities for unveiling new biomarkers and therapeutic targets, as well as fostering the development of personalized treatment strategies based on protein expression patterns associated with treatment response. In conclusion, proteomics holds great promise for advancing our understanding of pancreatic cancer biology and improving patient outcomes. It is essential to maintain momentum in investment and innovation in this arena to unearth more groundbreaking discoveries and transmute them into practical diagnostic and therapeutic strategies in the clinical context. |
format | Online Article Text |
id | pubmed-10443269 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104432692023-08-23 Proteomics-Driven Biomarkers in Pancreatic Cancer Ramalhete, Luís Vigia, Emanuel Araújo, Rúben Marques, Hugo Pinto Proteomes Review Pancreatic cancer is a devastating disease that has a grim prognosis, highlighting the need for improved screening, diagnosis, and treatment strategies. Currently, the sole biomarker for pancreatic ductal adenocarcinoma (PDAC) authorized by the U.S. Food and Drug Administration is CA 19-9, which proves to be the most beneficial in tracking treatment response rather than in early detection. In recent years, proteomics has emerged as a powerful tool for advancing our understanding of pancreatic cancer biology and identifying potential biomarkers and therapeutic targets. This review aims to offer a comprehensive survey of proteomics’ current status in pancreatic cancer research, specifically accentuating its applications and its potential to drastically enhance screening, diagnosis, and treatment response. With respect to screening and diagnostic precision, proteomics carries the capacity to augment the sensitivity and specificity of extant screening and diagnostic methodologies. Nonetheless, more research is imperative for validating potential biomarkers and establishing standard procedures for sample preparation and data analysis. Furthermore, proteomics presents opportunities for unveiling new biomarkers and therapeutic targets, as well as fostering the development of personalized treatment strategies based on protein expression patterns associated with treatment response. In conclusion, proteomics holds great promise for advancing our understanding of pancreatic cancer biology and improving patient outcomes. It is essential to maintain momentum in investment and innovation in this arena to unearth more groundbreaking discoveries and transmute them into practical diagnostic and therapeutic strategies in the clinical context. MDPI 2023-08-07 /pmc/articles/PMC10443269/ /pubmed/37606420 http://dx.doi.org/10.3390/proteomes11030024 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ramalhete, Luís Vigia, Emanuel Araújo, Rúben Marques, Hugo Pinto Proteomics-Driven Biomarkers in Pancreatic Cancer |
title | Proteomics-Driven Biomarkers in Pancreatic Cancer |
title_full | Proteomics-Driven Biomarkers in Pancreatic Cancer |
title_fullStr | Proteomics-Driven Biomarkers in Pancreatic Cancer |
title_full_unstemmed | Proteomics-Driven Biomarkers in Pancreatic Cancer |
title_short | Proteomics-Driven Biomarkers in Pancreatic Cancer |
title_sort | proteomics-driven biomarkers in pancreatic cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443269/ https://www.ncbi.nlm.nih.gov/pubmed/37606420 http://dx.doi.org/10.3390/proteomes11030024 |
work_keys_str_mv | AT ramalheteluis proteomicsdrivenbiomarkersinpancreaticcancer AT vigiaemanuel proteomicsdrivenbiomarkersinpancreaticcancer AT araujoruben proteomicsdrivenbiomarkersinpancreaticcancer AT marqueshugopinto proteomicsdrivenbiomarkersinpancreaticcancer |